Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
ENDRA Life Sciences Inc. (NDRA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 07/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/28/2023 |
S-1MEF
| Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]: |
| 04/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/18/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
SC 13G
| bryan michael sr reports a 6.1% stake in ENDRA LIFE SCIENCES, INC. |
| 02/01/2023 |
4
| Basenese Lou (Director) has filed a Form 4 on ENDRA Life Sciences Inc.|
Txns:
| Granted 6,746 options
@ $4.02, valued at
$27.1k
|
|
| 02/01/2023 |
4
| Tokman Alexander Y (Director) has filed a Form 4 on ENDRA Life Sciences Inc.|
Txns:
| Granted 9,621 options
@ $4.02, valued at
$38.7k
|
|
| 02/01/2023 |
4
| Harsh Michael (Director) has filed a Form 4 on ENDRA Life Sciences Inc.|
Txns:
| Granted 9,634 options
@ $4.02, valued at
$38.7k
|
|
| 02/01/2023 |
4
| DIGIANDOMENICO ANTHONY (Director) has filed a Form 4 on ENDRA Life Sciences Inc.|
Txns:
| Granted 9,621 options
@ $4.02, valued at
$38.7k
|
|
| 02/01/2023 |
4
| Pestrikova Irina (Senior Director, Finance) has filed a Form 4 on ENDRA Life Sciences Inc.|
Txns:
| Granted 8,000 options
@ $4.02, valued at
$32.2k
|
|
| 02/01/2023 |
4
| Thornton Michael Milos (Chief Technology Officer) has filed a Form 4 on ENDRA Life Sciences Inc.|
Txns:
| Granted 68,066 options
@ $4.02, valued at
$273.6k
|
|
| 02/01/2023 |
4
| Michelon Francois Roger (CEO) has filed a Form 4 on ENDRA Life Sciences Inc.|
Txns:
| Granted 69,531 options
@ $4.02, valued at
$279.5k
|
|
| 12/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/08/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
8-K
| Quarterly results |
|
|
|